| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cytochrome P450 39A1; EC 1.14.13.99; 24-hydroxycholesterol 7-alpha-hydroxylase; Oxysterol 7-alpha-hydroxylase; Hcyp39a1 |
| Entrez GeneID | 51302; |
| WB Predicted band size | 54kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human Cytochrome P450 39A1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **Cytochrome P450 3A4 (CYP3A4)** 和 **CYP39A1** 抗体的参考文献(已修正可能的拼写误差)，涵盖抗体开发和应用：
---
1. **文献名称**: *"Production and characterization of a monoclonal antibody highly specific for human CYP3A4"*
**作者**: Wang H, Tompkins LM.
**摘要**: 开发了一种高特异性的单克隆抗体，用于检测人CYP3A4蛋白，并通过Western blot和免疫组化验证其在肝微粒体中的表达，证明其不与其他CYP3A亚型交叉反应。
2. **文献名称**: *"Immunoquantification of CYP3A4 in human liver microsomes by a monoclonal antibody-based ELISA"*
**作者**: Gunes A, Dahl ML.
**摘要**: 建立了一种基于单克隆抗体的ELISA方法，定量分析人肝微粒体中CYP3A4的表达水平，为药物代谢研究提供工具，结果显示个体间表达差异显著。
3. **文献名称**: *"CYP39A1. a key enzyme in alternative bile acid synthesis pathways: generation of specific antibodies and localization in human tissues"*
**作者**: Honda A, Miyazaki T, Ikegami T.
**摘要**: 制备了针对人CYP39A1的多克隆抗体，证实其在胆固醇和胆汁酸代谢中的作用，通过免疫组化发现CYP39A1主要在肝脏和小肠中表达。
4. **文献名称**: *"Antibody-based profiling of CYP3A4 and CYP3A5 in cancer cell lines: implications for drug resistance"*
**作者**: Rodriguez-Antona C, Jover R, Gomez-Lechon MJ.
**摘要**: 利用特异性抗体分析癌细胞系中CYP3A4和CYP3A5的表达，发现其与化疗药物代谢及耐药性相关，抗体可用于临床样本的快速筛查。
---
**备注**：若需CYP39A1相关文献，建议补充关键词“oxysterol metabolism”或“alternative bile acid synthesis”进一步检索;若目标为CYP3A4(常见药物代谢酶)，可扩展至“pharmacogenomics”或“drug-drug interaction”领域。
Cytochrome P450 39A1 (CYP39A1) is a member of the cytochrome P450 enzyme superfamily, which plays a critical role in the metabolism of endogenous and exogenous compounds, including lipids, drugs, and xenobiotics. Specifically, CYP39A1 is involved in the alternative pathway of bile acid synthesis, catalyzing the 7α-hydroxylation of 24-hydroxycholesterol—a key step in regulating cholesterol homeostasis. Its expression is primarily detected in the liver and brain, linking it to lipid metabolism and neurodegenerative disorders.
Antibodies targeting CYP39A1 are essential tools for studying its expression, localization, and function in biological systems. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate tissue-specific expression patterns or alterations in disease states. For instance, research has explored CYP39A1's role in metabolic syndromes, liver diseases, and Alzheimer's disease, where dysregulation of cholesterol metabolism is implicated. Commercially available CYP39A1 antibodies are typically raised in rabbits or mice, with validation data confirming specificity through knockout controls or siRNA knockdown. Challenges in antibody development include ensuring minimal cross-reactivity with other P450 isoforms due to structural similarities. Overall, CYP39A1 antibodies provide critical insights into cholesterol-related pathways and potential therapeutic targets.
×
